ArticleAbdominal radiology (New York)2026
Habitat-based radiomics-clinical analysis for early prediction of bladder cancer recurrence: a retrospective cohort study.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeA high recurrence rate is a serious problem in the bladder cancer (BC) treatment. To develop a habitat-based radiomics-clinical model for noninvasive recurrence prediction in BC patients undergoing transurethral resection of bladder tumor (TURBT) or radical cystectomy (RC).
methodsWe retrospectively enrolled 294 BC patients who underwent TURBT or RC at our Hospital. Tumor regions of interest (ROIs) were automatically segmented and manually checked. Voxel-wise radiomic features were extracted. The K-means clustering algorithm was applied to perform cluster analysis on the extracted features. The Calinski-Harabasz (CH) index was calculated to determine the optimal number of clusters (the one yielding the highest CH value). Subsequently, features from these subregions were extracted and further filtered using the t-test and Pearson correlation analysis. The final feature set was selected through the least absolute shrinkage and selection operator regression. The dataset was randomly divided into the training (n = 235) and validation (n = 59) sets (8:2 ratio) for model training and evaluation. The habitat-based radiomics model based on Support Vector Machine (SVM) was developed based on the final feature set. Additionally, we combined clinical risk factors to establish and validate a radiomics-clinical model.
resultsWe divided the tumor ROIs into three subregions. The Areas Under the Curve (AUCs) for the habitat-based radiomics-model were 0.870 (95% confidence interval [CI]: 0.825-0.914) and 0.865 (95% CI: 0.774-0.956) in the training and validation set. The radiomics-clinical model, incorporating tumor grades and intravesical therapy, achieved AUCs of 0.883 (95% CI: 0.842-0.924) and 0.956 (95% CI: 0.912-1.000) in the training and validation sets, respectively.
conclusionsThe habitat-based radiomics-clinical model demonstrated superior performance in predicting BC recurrence.
Indexed as
Identifiers
42012493What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.